DexCom, Inc.
DXCM
株式のランク
#758
DexCom, Inc. is a medical technology company primarily focused on innovating,... DexCom, Inc. is a medical technology company primarily focused on innovating, developing, and marketing continuous glucose monitoring (CGM) systems. Operating across the United States and internationally, the firm provides its solutions for individuals managing diabetes as well as for healthcare practitioners. Its product portfolio features the DexCom G6, a comprehensive CGM system for diabetes management; the Dexcom Real-Time API, enabling authorized third-party developers to integrate live CGM data into their digital health applications; the Dexcom ONE, which aims to supersede traditional finger-prick blood glucose testing for treatment decisions; and Dexcom Share, a remote monitoring platform. The company is also developing the Dexcom G7, its next-generation CGM system. Furthermore, DexCom, Inc. has a licensing and collaboration agreement with Verily Life Sciences LLC and Verily Ireland Limited to advance blood-based or interstitial glucose monitoring products. The company directly sells its offerings to specialists such as endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and maintains its headquarters in San Diego, California.
株価
$85.72
最終同期: 2026-10-20
時価総額
$32.35B
変化（1日）
-0.30%
変化（1年）
22.90%
国
US
取引 DexCom, Inc. (DXCM)
カテゴリー
Healthcare
DexCom, Inc.（DXCM）の株式分割履歴
DexCom, Inc.株（シンボル：DXCM）は合計で1回の株式分割を実施しました。
最新の株式分割はJun 13, 2022に行われました。
Jun 13, 2022より前に購入されたDXCM株は、現在4DXCM株に相当します。
最新の株式分割はJun 13, 2022に行われました。
Jun 13, 2022より前に購入されたDXCM株は、現在4DXCM株に相当します。
株式分割一覧
| 年 | 株式分割 | 分割比率 | 累積分割比率 |
|---|---|---|---|
| 2022-06-13 | 4:1 | x4 | x4 |
類似企業または競合他社の株式分割
| 企業 | 株式分割の回数 | 累積分割比率 | 国 |
|---|---|---|---|
| 9 | x285 |
US
|
|
| 7 | x127 |
IE
|
|
| 9 | x162 |
US
|
|
| 2 | x4 |
US
|
|
| 0 | - |
DE
|
